A pioneering study, presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2024, demonstrates the significant potential of semaglutide in treating hidradenitis suppurative (HS), a common and chronic skin condition, in people with obesity.
European Academy of Dermatology and Venereology Congress 2024Sep 24 2024 A pioneering study, presented today at the European Academy of Dermatology and Venereology Congress 2024, demonstrates the significant potential of semaglutide in treating hidradenitis suppurative , a common and chronic skin condition, in people with obesity.
HS is currently estimated to affect approximately 1 in 100 people, with obesity being a significant risk factor. The condition is characterized by painful abscesses and scarring, which can severely impact patients' quality of life. Despite advancements in managing HS, effective treatments remain limited and can cause serious side effects, highlighting a need for alternative and better-tolerated treatment options.
Researchers monitored changes in body mass index , weight, flare frequency, Dermatology Life Quality Index value, and pain levels before and after starting semaglutide, as well as biochemical markers, including C-reactive protein , glucose and haemoglobin A1c levels.Patients experienced fewer HS flare-ups, with the frequency of these episodes reducing from an average of once every 8.5 weeks to once every 12 weeks.
Further positive changes were observed in the biochemical markers assessed. HbA1c levels decreased from 39.3 to 36.6, indicating better glycaemic control, while average CRP levels fell from 7.8 to 6.9, signifying reduced inflammation.
Skin Chronic Dermatology Frequency Glucagon Hba1c Hospital Obesity Research Weight Loss
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Semaglutide's cardiovascular benefits are maintained in people with impaired kidney function, research findsThe anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with overweight or obesity who don't have diabetes, whether or not they also have impaired kidney function, according to new research to be presented at this year's Annual Meeting of...
Read more »
Research highlights cardiovascular benefits of semaglutide for overweight adults with impaired kidney functionThe anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with overweight or obesity who don't have diabetes, whether or not they also have impaired kidney function, according to new research to be presented at this year's Annual Meeting of...
Read more »
Semaglutide and tirzepatide significantly improve weight loss and glycemic control in type 1 diabetesSemaglutide and tirzepatide treatment lead to significant weight loss and improve blood sugar control in individuals with type 1 diabetes (T1D) who are living with overweight or obesity, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September) has found.
Read more »
Semaglutide reduced mortality in obese patients by lowering infection-related deaths during COVID-19 pandemicSemaglutide significantly reduces all-cause mortality in non-diabetic obese patients, particularly by lowering infection-related deaths during the COVID-19 pandemic. However, the study's findings should be interpreted with caution due to potential competing risks and unique pandemic circumstances.
Read more »
Innovative semaglutide hydrogel could reduce diabetes shots to once a monthFrench researchers have developed a new drug delivery system that could cut the dosing schedule for type 2 diabetes and weight control drug semaglutide to just once a month, according to new research to be presented at this year's annual meeting of the European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).
Read more »
New hydrogel system could extend semaglutide dosing to once a month for type 2 diabetes patientsFrench researchers have developed a new drug delivery system that could cut the dosing schedule for the type 2 diabetes and weight control drug semaglutide to just once a month, according to new research to be presented at this year's annual meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).
Read more »